Further studies are warranted to determine more precisely the mechanism tying these pathophysiological processes together and whether serum biomarkers of CKD-mineral and bone disorder, such as FGF-23, can be used clinically for better CV risk stratification. Here, FGF23 is linked to chronic kidney disease.